Table 1.

Summary of baseline characteristics of major SGLT2i trials

Clinical Trial
Cardiovascular Outcome TrialKidney Outcome TrialHeart Failure Outcome Trial
EMPA-REGCANVASDECLARE-TIMI 58CREDENCEDAPA-HF
DrugEmpagliflozinCanagliflozinDapagliflozinCanagliflozinDapagliflozin
No. of patients702010,14217,16044014744
Age, yr6363646366
Duration of DM, yr1413.51115.5NR
BMI, kg/m23132323128
HbA1c, %8.18.28.38.37.4a
Atherosclerotic cardiovascular disease, %100664151NR
Heart failure, %10141015100
Reduced eGFR, %b262074140
Mean eGFR, ml/min per 1.73 m27476855666
UACR<30 mg/g, %6070691NR
UACR 30–300 mg/g, %29222411NR
UACR≥300 mg/g, %118788NR
Insulin, %4850416625a
Sulfonylureas, %4343432920a
ACEi/ARB, %85808110094
Diuretics, %4444414793
  • SGLT2i, sodium glucose co-transporter 2 inhibitor; EMPA-REG, The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose; CANVAS, The multicenter Canagliflozin Cardiovascular Assessment Study; DECLARE-TIMI 58, Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; CREDENCE, Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DM, diabetes mellitus; NR, not reported; BMI, body mass index; HbA1c, hemoglobin A1c; UACR, urinary albumin-to-creatinine ratio; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

  • a For patients with diabetes.

  • b eGFR<60 ml/min per 1.73 m2.